New Treatments for Melanoma and the MRF

Although the last time a new drug was approved for metastatic melanoma was over a decade ago, recent advances offer new hope for patients.  Two drugs, ipilimumab and PLX4032 have shown promising results and received significant coverage from the media.  The Melanoma Research Foundation (MRF) is committed to finding new treatments for those who have been diagnosed, and has played a pivotal role in research related to the development of these drugs.  Because most experts are convinced that a single drug won’t be the answer to metastatic melanoma, the MRF has launched the MRF Breakthrough Consortium to find combination therapies that will accelerate the discovery of effective treatments.  You can learn more about MRF’s research initiatives through this report.